{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:11:56Z","timestamp":1793124716917,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016239","name":"University of Occupational and Environmental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016239","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Editage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Since molecularly targeted therapies are emerging for treating lupus nephritis (LN), this study aimed to assess the immunohistochemical findings of the cytokines in renal tissue and their pathological and clinical relevance in LN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fifty patients with proliferative LN formed the case group; 5 with LN class II, IgA nephropathy and 10 with idiopathic haematuria were enrolled as controls. Immunohistochemical analysis for CD3, CD20, interferon (IFN)-\u03b1, interleukin (IL)-12\/p40 and B-cell activating factor (BAFF) was performed by scoring the number of positive cells\/area of the cortex. All immunohistochemical investigations were performed on formalin-fixed paraffin-embedded renal tissue. Proliferative LN cases were grouped by the dominant expression of IFN-\u03b1, IL-12\/p40 and BAFF, and subsequently, clinicopathological features were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clinical data of patients with proliferative LN included urine protein creatinine ratio, 2.2 g\/gCre; anti-double-stranded DNA antibody, 200.9 IU\/mL; total complement activity (CH50), 21.9 U\/mL and SLE Disease Activity Index, 19.8 points. Proliferative LN cases, including class III (n=18) and IV (n=32), were classified into three subgroups according to the immunohistochemical score based on the dominancy of IFN-\u03b1 (n=17), IL-12 (n=16) and BAFF group (n=17) proteins. Hypocomplementaemia and glomerular endocapillary hypercellularity were significantly increased in the IFN-\u03b1 group, whereas chronic lesions were significantly higher in the IL-12 group (p&lt;0.05). The IFN-\u03b1 group had a poorer renal prognosis in treatment response after 52 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The immunohistochemistry (IHC) of IFN-\u03b1, IL-12 and BAFF for proliferative LN enabled grouping. Especially, the IFN-\u03b1 and IL-12 groups showed different clinicopathological features and renal prognoses. The results indicated the possibility of stratifying cases according to the IHC of target molecules, which might lead to precision medicine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2023-000962","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T21:10:23Z","timestamp":1689628223000},"page":"e000962","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Differential expression of IFN-\u03b1, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-2425","authenticated-orcid":false,"given":"Aya","family":"Nawata","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"},{"name":"Department of Pathology and Oncology, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hisano","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Kidney Center, University of Occupational and Environmental Health Hospital, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Shiba","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Hisaoka","sequence":"additional","affiliation":[{"name":"Department of Pathology and Oncology, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2025091515212905000_10.2.e000962.1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017"},{"key":"2025091515212905000_10.2.e000962.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664"},{"key":"2025091515212905000_10.2.e000962.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3936"},{"key":"2025091515212905000_10.2.e000962.4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney International"},{"key":"2025091515212905000_10.2.e000962.5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025091515212905000_10.2.e000962.6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1756-185X.13817","article-title":"State-of-the-art treatment of systemic lupus erythematosus","volume":"23","author":"Tanaka","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2025091515212905000_10.2.e000962.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02177-0","article-title":"The role of baseline Blys levels and type 1 interferon-inducible gene signature status in determining Belimumab response in systemic lupus erythematosus: a post hoc meta-analysis","volume":"22","author":"Wilkinson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025091515212905000_10.2.e000962.8","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2025091515212905000_10.2.e000962.9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab international study in lupus nephritis trial examined effects of Belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney International"},{"key":"2025091515212905000_10.2.e000962.10","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8142368","article-title":"Biologics in the treatment of lupus erythematosus: A critical literature review","volume":"2019","author":"Samotij","year":"2019","journal-title":"Biomed Res Int"},{"key":"2025091515212905000_10.2.e000962.11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array Digital enzyme-linked immunosorbent assay Quantification of serum interferon-\u0391","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025091515212905000_10.2.e000962.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212652"},{"key":"2025091515212905000_10.2.e000962.13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological Dmards based on characteristic phenotypes of peripheral T helper cells in Psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025091515212905000_10.2.e000962.14","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.40180","article-title":"Peripheral Immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients","volume":"69","author":"Kubo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025091515212905000_10.2.e000962.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2025091515212905000_10.2.e000962.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2025091515212905000_10.2.e000962.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2025091515212905000_10.2.e000962.18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14397595.2015.1060665","article-title":"Efficacy and safety of Rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025091515212905000_10.2.e000962.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014460"},{"key":"2025091515212905000_10.2.e000962.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"2025091515212905000_10.2.e000962.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2018.12.017","article-title":"Type I and II Interferons commit to abnormal expression of Chemokine receptor on B cells in patients with systemic lupus erythematosus","volume":"200","author":"Yoshikawa","year":"2019","journal-title":"Clin Immunol"},{"key":"2025091515212905000_10.2.e000962.22","doi-asserted-by":"crossref","unstructured":"Mavragani CP , Kirou KA , Seshan SV , et al . Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford) 2022:keac641. doi:10.1093\/rheumatology\/keac641","DOI":"10.1093\/rheumatology\/keac641"},{"key":"2025091515212905000_10.2.e000962.23","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-019-0473-3","article-title":"Publisher correction: the immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"key":"2025091515212905000_10.2.e000962.24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.kint.2020.08.006","article-title":"Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the renal pathology society","volume":"98","author":"Haas","year":"2020","journal-title":"Kidney Int"},{"key":"2025091515212905000_10.2.e000962.25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1984.75"},{"key":"2025091515212905000_10.2.e000962.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204837"},{"key":"2025091515212905000_10.2.e000962.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"2025091515212905000_10.2.e000962.28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1535370218824547","article-title":"IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus","volume":"244","author":"Larosa","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"key":"2025091515212905000_10.2.e000962.29","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/rheumatology\/keaa176","article-title":"Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and Activators of transcription 3 in lupus patients","volume":"59","author":"Lee","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025091515212905000_10.2.e000962.30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3892\/etm.2021.10059","article-title":"Interleukin-12 exacerbates symptoms in an MRL\/Mpj-Faslpr mouse model of systemic lupus erythematosus","volume":"21","author":"Li","year":"2021","journal-title":"Exp Ther Med"},{"key":"2025091515212905000_10.2.e000962.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03758.x"},{"key":"2025091515212905000_10.2.e000962.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4518"},{"key":"2025091515212905000_10.2.e000962.33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0961203317739132","article-title":"Profile of BAFF and its receptors\u2019 expression in lupus nephritis is associated with pathological classes","volume":"27","author":"Suso","year":"2018","journal-title":"Lupus"},{"key":"2025091515212905000_10.2.e000962.34","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020140","article-title":"Immune profiling and precision medicine in systemic lupus erythematosus","volume":"8","author":"Nagafuchi","year":"2019","journal-title":"Cells"},{"key":"2025091515212905000_10.2.e000962.35","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/rheumatology\/keac528","article-title":"SLE stratification based on BAFF and IFN-I Bioactivity for Biologics and implications of BAFF produced by glomeruli in lupus nephritis","volume":"62","author":"Itotagawa","year":"2023","journal-title":"Rheumatology (Oxford)"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2023-000962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:21:39Z","timestamp":1757974899000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2023-000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/lupus-2023-000962"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2023-000962","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}